Furthermore, bone marrow microenvironment-mediated resistance has been reported, involving upregulation of FLT3 ligand and fibroblast growth factor 2 (FGF2) by mesenchymal stromal cells, which activate AML cells via wild-type FLT3 and fibroblast growth factor receptor 1 (FGFR1) [21]. The gene discussed is FLT3; the disease is acute myeloid leukemia.